Prostate cancer most commonly metastasizes to bone, which accounts for roughly 84% of all metastatic cases. After bone, the next most frequent sites are distant lymph nodes (10.6%), liver (10.2%), and the lungs and chest area (9.1%), based on a population-level analysis of nearly 75,000 men with metastatic prostate cancer. Less commonly, it can reach the brain and other organs.
Bone Is the Primary Target
The bones of the pelvis and spine are the most frequent landing sites for prostate cancer cells that leave the prostate. From there, the disease can spread to the ribs and, over time, to other bones including the base of the skull. This strong preference for bone sets prostate cancer apart from many other cancers.
What makes prostate cancer bone metastases unusual is the type of damage they cause. Most cancers that spread to bone break it down, creating weak spots. Prostate cancer does the opposite in over 90% of cases: it triggers abnormal new bone growth at the metastatic site. These deposits are called osteoblastic lesions. Despite the extra bone formation, the new tissue is structurally disorganized, with immature bone and chaotic collagen fibers. The result is bone that looks denser on scans but is actually weaker than healthy bone. This leaves patients vulnerable to fractures, bone pain, and in the spine, compression of the spinal cord.
Spinal cord compression occurs in about 7% of men with prostate cancer. It typically announces itself with worsening back pain, and can progress to numbness, weakness in the legs, or loss of bladder and bowel control if the compressed area isn’t treated promptly. Persistent or worsening back pain in someone with known prostate cancer should always be taken seriously.
Lymph Nodes, Liver, and Lungs
Lymph nodes near the prostate (in the pelvis) are often the first stop for spreading cancer cells. When prostate cancer reaches lymph nodes outside the pelvis, such as those in the abdomen or chest, it’s classified as distant metastatic disease. Lymph node spread on its own tends to carry a better outlook than spread to internal organs.
Liver metastases appear in roughly 1 in 8 men with metastatic prostate cancer. Liver involvement tends to be more aggressive: median survival with liver metastases alone is about 10 months, compared to 44 months for bone-only metastases and about 32 months for lung-only metastases. Symptoms of liver spread can include nausea, vomiting, unintentional weight loss, and deep fatigue.
Lung metastases are present in about 12.5% of metastatic cases. They may cause shortness of breath or a persistent cough, though small lung deposits often produce no symptoms at all and are found incidentally on imaging.
Brain and Other Rare Sites
Brain metastases from prostate cancer are uncommon but not unheard of, appearing in roughly 8.7% of men in one large database study. When prostate cancer does reach the brain, the prognosis is poor: median survival is about 9.6 months. If bone metastases are also present, that drops to around 8 months. Symptoms depend on the location within the brain but can include headaches, confusion, vision changes, or difficulty with balance.
Other rare sites include the adrenal glands and, in very unusual cases, the skin. These are far less common and typically occur alongside spread to more typical locations.
How Prostate Cancer Cells Spread
Cancer cells leave the prostate through two main routes: the bloodstream and the lymphatic system. Some cells break away from the original tumor and slip into tiny blood vessels in or around the prostate. Others enter lymphatic channels, which eventually drain into the bloodstream anyway. Either route gives cancer cells access to distant organs.
The process isn’t always active. Sometimes tumor cells are passively shed into nearby vessels. In other cases, cancer cells undergo a transformation that makes them more mobile. They shift from behaving like stationary tissue cells to acting more like cells that can crawl through surrounding structures. Chemical signals from lymph nodes can also actively recruit cancer cells toward them, which helps explain why lymph node involvement is so common in prostate cancer.
How Metastases Are Found
Traditional bone scans have long been the standard for detecting bone metastases, and they still work reasonably well, catching about 86% of true cases. But a newer type of imaging, the PSMA PET scan, has significantly improved detection. PSMA PET scans target a protein found on prostate cancer cells and pick up 97% of true cases with virtually no false positives. This makes them especially useful for finding small metastases that older scans would miss, which can change treatment decisions.
CT scans and MRI remain important for evaluating soft-tissue spread to organs like the liver, lungs, and brain. In practice, doctors often combine multiple imaging methods to get a complete picture of where the cancer has traveled.
How Metastatic Stage Affects Outlook
When prostate cancer is caught before it spreads, the five-year survival rate is extremely high. Once it reaches distant sites, the five-year relative survival rate drops to about 37.9%, according to the most recent national data. But that number is an average across all metastatic cases, and it masks wide variation depending on where the cancer has spread.
Bone-only metastases carry the longest median survival among metastatic sites, at roughly 44 months. Lung-only metastases fall in the middle at about 32 months. Liver and brain metastases are associated with the shortest survival times, around 10 months and 9.6 months respectively. When multiple organs are involved simultaneously, survival times shorten further. For example, men with both liver and bone metastases have a median survival of just 5.4 months.
Symptoms That Signal Spread
The most common symptom of metastatic prostate cancer is pain, particularly in the back, hips, or pelvis. This pain tends to worsen gradually over weeks or months rather than appearing suddenly. Other signs include deep fatigue that doesn’t improve with rest, unexplained weight loss, needing to urinate more often, and nausea or vomiting.
Because bone metastases are so dominant in prostate cancer, bone pain is often the symptom that first alerts men (and their doctors) to metastatic disease. Pain that is persistent, worsening, or present at night warrants investigation, especially in men with a history of prostate cancer or elevated PSA levels.